Swiss National Bank Kiniksa Pharmaceuticals, Ltd. Transaction History

Swiss National Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$14.37 - $19.07 $73,287 - $97,257	-5,100 Reduced 8.4%	55,600 $975,000
Q2 2023 Aug 09, 2023	SELL	$10.44 - $16.48 $66,816 - $105,472	-6,400 Reduced 9.54%	60,700 $854,000
Q1 2023 May 10, 2023	SELL	$10.7 - $15.79 $83,460 - $123,162	-7,800 Reduced 10.41%	67,100 $721,000
Q4 2022 Feb 08, 2023	BUY	$11.42 - $17.05 $29,692 - $44,330	2,600 Added 3.6%	74,900 $1.12 Million
Q2 2022 Aug 09, 2022	BUY	$7.6 - $11.41 $92,720 - $139,202	12,200 Added 20.3%	72,300 $701,000
Q1 2022 May 09, 2022	BUY	$9.3 - $12.37 $67,890 - $90,301	7,300 Added 13.83%	60,100 $597,000
Q2 2021 Aug 06, 2021	SELL	$13.22 - $19.09 $18,508 - $26,726	-1,400 Reduced 2.58%	52,800 $736,000
Q1 2021 May 07, 2021	BUY	$16.68 - $23.97 $28,356 - $40,749	1,700 Added 3.24%	54,200 $1 Million
Q3 2020 Nov 09, 2020	BUY	$15.21 - $25.53 $211,419 - $354,867	13,900 Added 36.01%	52,500 $804,000
Q2 2020 Aug 05, 2020	BUY	$15.08 - $26.0 $582,088 - $1 Million	38,600 New	38,600 $984,000
Q4 2019 Feb 06, 2020	SELL	$5.24 - $12.96 $102,180 - $252,720	-19,500 Closed	0 $0
Q2 2019 Aug 02, 2019	BUY	$13.2 - $20.39 $257,400 - $397,605	19,500 New	19,500 $264,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.